Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)

Circulation

Volumn 97, Issue 15, 1998, Pages 1440-1445

  Packard, Chris J ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Cholesterol; Coronary disease; Risk factors

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; TRIACYLGLYCEROL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK MANAGEMENT; SECONDARY PREVENTION; SURVIVAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032554676     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.15.1440     Document Type: Article

References (30)

1. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators. Br Heart J. 1978;40:1069-1118.
2. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251: 351-364.
3. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pakkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment changes in risk factors and incidence of coronary heart disease. N Engl J Med. 1987;317: 1237-1245.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;334: 1001-1009.
7. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Prac Natl Acad Sci U S A. 1983;80:4124-4128.
8. Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, Vallance BD, Lorimer AR, Shepherd J. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb. 1993;13:170-189.
9. Bradley WA, Hwang S-LC, Karlin JB, Lin AHY, Prasad SC, Gotto AM Jr, Gianturco SH. Low density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very low density lipoprotein to low density lipoproteins. J Biol Chem. 1984;259:14728-14735.
10. The Lipid Research Clinic Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
11. Manninen V, Elo O, Frick H, Haapa K, Heinonen P, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
12. West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men age 45-64 years: trial design. J Clin Epidemiol. 1992;45:849-860.
13. Lipid Research Clinics Manual of Laboratory Operations. Washington, DC: Government Printing Office; 1975. DHEW publication No. NIH 85-268.
14. West of Scotland Coronary Prevention Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol. 1995;76:485-491.
15. Collett D. Modelling Survival Data in Medical Research. London, UK: Chapman Hall; 1994.
16. West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol. 1997;74:756-762.
17. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1990;121:293-298.
18. Anderson KM, Wilson PWF, Odell PM. Kannel WB. An updated coronary risk profile. Circulation. 1991;83:357-363.
19. Abbott RD, McGee D. The Framingham Study, Section 37: The Probability of Developing Certain Cardiovascular Diseases in Eight Years at Specified Values of Some Characteristics. Washington, DC: 1987: NIH publication No. 87-2284.
20. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1990;11:1-14.
21. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men. Lancet. 1986;2:933-936.
22. Scandinavian Simvastatin Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
23. Knopp RH, Illingworth DR, Stern EA, Ginsberg HN, Broyles EE, Behounek BD. Effect of pravastatin in the treatment of patients with type III hyperlipoproteinemia. Am J Ther. 1996;3:755-762.
24. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
25. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90: 42-49.
26. Hodis HN, Mack WJ. Triglyceride rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol. 1995;6:209-214.
27. Lacoste L, Lam J, Hung J, Letchacovski G, Solymoss CB, Waters D. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;92:3172-3177.
28. Sandset PM, Lund H, Abildgaard U, Ose L. Treatment with hydroxy-methylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb. 1991;11:138-145.
29. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS Jr, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leion AS, Chalmers TC, and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on the surgical control of the hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
30. Gaw A. Can the clinical efficacy of HMG CoA reductase inhibitors be explained solely by their effects on LDL cholesterol? Atherosclerosis. 1996;125:267-269.